Overview

  • Product name

    Anti-non-muscle Myosin IIA antibody
    See all non-muscle Myosin IIA primary antibodies
  • Description

    Rabbit polyclonal to non-muscle Myosin IIA
  • Host species

    Rabbit
  • Tested applications

    Suitable for: ICC/IF, WBmore details
  • Species reactivity

    Reacts with: Mouse, Rat, Human
    Predicted to work with: Chicken, Xenopus laevis
  • Immunogen

    Synthetic peptide within Human non-muscle Myosin IIA aa 250-350 conjugated to keyhole limpet haemocyanin. The exact sequence is proprietary.
    (Peptide available as ab99879)

  • Positive control

    • WB: Wild-type HAP1, HL-60, Jurkat, NIH/3T3, PC-12, HeLa and HEK-293 cell lysate. Human kidney tissue lysate. Mouse kidney and lung tissue lysate. ICC/IF: HeLa cells.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage buffer

    Preservative: 0.02% Sodium Azide
    Constituents: 1% BSA, PBS, pH 7.4
  • Concentration information loading...
  • Purity

    Immunogen affinity purified
  • Clonality

    Polyclonal
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab75590 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use a concentration of 5 µg/ml.
WB Use a concentration of 1 µg/ml. Detects a band of approximately 227 kDa (predicted molecular weight: 227 kDa).

Target

  • Function

    Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.
  • Tissue specificity

    In the kidney, expressed in the glomeruli. Also expressed in leukocytes.
  • Involvement in disease

    Defects in MYH9 are the cause of May-Hegglin anomaly (MHA) [MIM:155100]. MHA is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukokyte inclusions appearing as highly parallel paracrystalline bodies.
    Defects in MYH9 are the cause of Sebastian syndrome (SBS) [MIM:605249]. SBS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are smaller and less organized than in May-Hegglin anomaly.
    Defects in MYH9 are the cause of Fechtner syndrome (FTNS) [MIM:153640]. FTNS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are small and poorly organized. Additionally, FTNS is distinguished by Alport-like clinical features of sensorineural deafness, cataracts and nephritis.
    Defects in MYH9 are the cause of Alport syndrome with macrothrombocytopenia (APSM) [MIM:153650]. APSM is an autosomal dominant disorder characterized by the association of ocular lesions, sensorineural hearing loss and nephritis (Alport syndrome) with platelet defects.
    Defects in MYH9 are the cause of Epstein syndrome (EPS) [MIM:153650]. EPS is an autosomal dominant disorder characterized by the association of macrothrombocytopathy, sensorineural hearing loss and nephritis.
    Defects in MYH9 are the cause of deafness autosomal dominant type 17 (DFNA17) [MIM:603622]. DFNA17 is a form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA17 is characterized by progressive hearing impairment and cochleosaccular degeneration.
    Defects in MYH9 are the cause of macrothrombocytopenia with progressive sensorineural deafness (MPSD) [MIM:600208]. MPSD is an autosomal dominant disorder characterized by the association of macrothrombocytopathy and progressive sensorineural hearing loss without renal dysfunction.
    Note=Subjects with mutations in the motor domain of MYH9 present with severe thrombocytopenia and develop nephritis and deafness before the age of 40 years, while those with mutations in the tail domain have a much lower risk of noncongenital complications and significantly higher platelet counts. The clinical course of patients with mutations in the four most frequently affected residues of MYH9 (responsible for 70% of MYH9-related cases) were evaluated. Mutations at residue 1933 do not induce kidney damage or cataracts and cause deafness only in the elderly, those in position 702 result in severe thrombocytopenia and produce nephritis and deafness at a juvenile age, while alterations at residue 1424 or 1841 result in intermediate clinical pictures.
    Note=Genetic variations in MYH9 are associated with non-diabetic end stage renal disease (ESRD).
  • Sequence similarities

    Contains 1 IQ domain.
    Contains 1 myosin head-like domain.
  • Domain

    The rodlike tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides, characteristic for alpha-helical coiled coils.
  • Post-translational
    modifications

    ISGylated.
  • Information by UniProt
  • Database links

  • Alternative names

    • BDPLT 6 antibody
    • BDPLT6 antibody
    • Cellular myosin heavy chain antibody
    • Cellular myosin heavy chain type A antibody
    • DFNA 17 antibody
    • DFNA17 antibody
    • EPSTS antibody
    • FTNS antibody
    • MGC104539 antibody
    • MHA antibody
    • MYH 2A antibody
    • MYH 9 antibody
    • MYH2A antibody
    • MYH9 antibody
    • MYH9_HUMAN antibody
    • MYHas8 antibody
    • MyHC 2A antibody
    • MyHC IIa antibody
    • MyHC2A antibody
    • MyHCIIa antibody
    • MYHSA 2 antibody
    • MYHSA2 antibody
    • Myosin 9 antibody
    • Myosin heavy chain 9 antibody
    • Myosin heavy chain 9 non muscle antibody
    • Myosin heavy chain antibody
    • Myosin heavy chain non muscle IIa antibody
    • Myosin heavy chain nonmuscle IIa antibody
    • Myosin heavy polypeptide 2 antibody
    • Myosin heavy polypeptide 9 non muscle antibody
    • Myosin-9 antibody
    • Myosin9 antibody
    • NMHC II A antibody
    • NMMHC A antibody
    • NMMHC II a antibody
    • NMMHC II-a antibody
    • NMMHC IIA antibody
    • NMMHC-A antibody
    • NMMHC-IIA antibody
    • NMMHCA antibody
    • Non muscle myosin heavy chain A antibody
    • Non muscle myosin heavy chain antibody
    • Non muscle myosin heavy chain II A antibody
    • Non muscle myosin heavy polypeptide 9 antibody
    • non-muscle IIa antibody
    • Non-muscle myosin heavy chain A antibody
    • Non-muscle myosin heavy chain IIa antibody
    • Nonmuscle myosin heavy chain A antibody
    • Nonmuscle myosin heavy chain II A antibody
    • type A antibody
    see all

Images

  • Lane 1: Wild-type HAP1 cell lysate (20 µg)
    Lane 2: non-muscle Myosin IIA knockout HAP1 cell lysate (20 µg)
    Lane 3: HeLa cell lysate (20 µg)
    Lane 4: HEK-293 cell lysate (20 µg)
    Lanes 1 - 4: Merged signal (red and green). Green - ab75590 observed at 230 kDa. Red - loading control, ab18058, observed at 124 kDa.

    ab75590 was shown to recognize non-muscle Myosin IIA in wild-type HAP1 cells along with additonal cross-reactive bands. No band was observed when non-muscle Myosin IIA knockout samples examined. Wild-type and non-muscle Myosin IIA knockout samples were subjected to SDS-PAGE. ab75590 at a concentration of 1 µg/ml and ab18058 (loading control to Vinculin) at a dilution of 1/1,000 were incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.

  • ICC/IF image of ab75590 stained HeLa (Human epithelial cell line from cervix adenocarcinoma) cells.

    The cells were 4% formaldehyde fixed (10 minutes) and then incubated in 1% BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1 hour to permeabilize the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab75590 at 5 µg/ml overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti- rabbit IgG (H+L) used at a 1/1,000 dilution for 1 hour. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1 hour. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43 µM.

  • All lanes : Anti-non-muscle Myosin IIA antibody (ab75590) at 1 µg/ml

    Lane 1 : HeLa (Human epithelial carcinoma cell line) whole cell lysate
    Lane 2 : HL-60 (Human promyelocytic leukemia cell line) whole cell lysate
    Lane 3 : Jurkat (Human T cell lymphoblast-like cell line) whole cell lysate
    Lane 4 : HEK-293 (Human embryonic kidney cell line) whole cell lysate
    Lane 5 : Human kidney tissue lysate - total protein (ab30203)

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 227 kDa
    Observed band size: 227 kDa
    Additional bands at: 100 kDa, 35 kDa, 45 kDa. We are unsure as to the identity of these extra bands.


    Exposure time: 30 seconds
  • All lanes : Anti-non-muscle Myosin IIA antibody (ab75590) at 1 µg/ml

    Lane 1 : NIH/3T3 (Mouse embryonic fibroblast cell line) whole cell lysate
    Lane 2 : Mouse kidney tissue lysate
    Lane 3 : Mouse lung tissue lysate
    Lane 4 : PC-12 (Rat adrenal pheochromocytoma cell line) whole cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 227 kDa
    Observed band size: 227 kDa
    Additional bands at: 35 kDa, 43 kDa. We are unsure as to the identity of these extra bands.


    Exposure time: 1 minute

References

This product has been referenced in:

  • Mudersbach T  et al. Epigenetic control of the angiotensin-converting enzyme in endothelial cells during inflammation. PLoS One 14:e0216218 (2019). Read more (PubMed: 31042763) »
  • Laban H  et al. VASP regulates leukocyte infiltration, polarization, and vascular repair after ischemia. J Cell Biol 217:1503-1519 (2018). Read more (PubMed: 29507126) »
See all 4 Publications for this product

Customer reviews and Q&As

1-6 of 6 Abreviews or Q&A

Application
Western blot
Sample
Mouse Cell lysate - whole cell (Hepatocytes)
Gel Running Conditions
Reduced Denaturing (8% SDS-PAGE)
Loading amount
35 µg
Specification
Hepatocytes
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C

Dr. Armen Petrosyan

Verified customer

Submitted Feb 12 2019

Application
Immunocytochemistry/ Immunofluorescence
Sample
Rat Cell (Rat hepatocytes)
Permeabilization
Yes - 0.2% Triton X-100 in PBS
Specification
Rat hepatocytes
Blocking step
Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 22°C
Fixative
Formaldehyde

Dr. Armen Petrosyan

Verified customer

Submitted Apr 05 2017

Application
Western blot
Sample
Human Cell lysate - whole cell (LNCaP - prostate cancer cells)
Gel Running Conditions
Reduced Denaturing (4-15% SDS PAGE)
Loading amount
20 µg
Specification
LNCaP - prostate cancer cells
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C

Dr. Armen Petrosyan

Verified customer

Submitted Mar 31 2017

Application
Immunocytochemistry/ Immunofluorescence
Sample
Human Cell (LNCaP - prostate cancer cells)
Permeabilization
No
Specification
LNCaP - prostate cancer cells
Blocking step
Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 22°C
Fixative
Methanol

Dr. Armen Petrosyan

Verified customer

Submitted Feb 13 2017

Answer

I am very pleased to hear you would like to accept our offer and test ab75590 and ab67758 on chicken samples by ICC/IF. These codes will give you: one free primary antibody per code before the expiration date. To redeem this offer, please submit an Abreview and include the code in the “Additional Comments” section so we know the Abreview is for this promotion. Please remember that submission of the Abreview is sufficient for the discount code to become active.


For more information on how to submit an Abreview, please visit the site: www.abcam.com/Abreviews.


We publish positive and negative Abreviews on our datasheets so please submit the results of your tests regardless of the outcome. The code will be active once the Abreview has been submitted and can be redeemed in one of the following ways: 1) Call to place your order and mention the code to our customer service department; 2) Include the code in your fax order; 3) Place your order on the web and enter the promotional code.

Any feedback that you can provide will be greatly appreciated, whether positive or negative. If you have any further questions, please do not hesitate to contact us. We look forward to receiving your Abreview and wish you luck with your research.

The terms and conditions applicable to this offer can be found here: www.abcam.com/collaborationdiscount.

Read More

Answer

Thank you very much for your interest in our products. Unfortunately, non of the anti -non-muscle heavy chain Myosin antibodies is suitable for drosophila. The same is true for the anti collagen antibody. We usually expect a cross-reaction from 85% homology and up. In these cases the best homology I could find was 42%. I would like to recommend checking the Biocompare website which has an excellent antibody search facility that includes many suppliers. The links are: www.biocompare.com http://www.biocompare.com/ProductCategories/2045/Antibodies.html I hope this information is nevertheless helpful to you. Please do not hesitate to contact me if you have any further questions in this regard.

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up